Communiqués Structure Therapeutics Inc.

Actions

GPCR

US86366E1064

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 11/08/2026			Varia. 5j.	Varia. 1 janv.
52,13 ^USD	-3,11%		+5,02%	-25,05%

06/08	Structure Therapeutics Inc. prévoit de publier de nouvelles données sur les essais cliniques de l'aléniglipron au second semestre 2026	CI
06/08	Structure Therapeutics Inc. annonce la nomination de John Berrios au poste de Chief Commercial Officer	CI

Communiqués

06/08	Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights	GL
06/08	Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights	AQ
05/06	Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity	GL
26/05	Structure Therapeutics Announces Participation in Upcoming Investor Conferences	GL
08/05	Structure Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights	GL
07/05	Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights	AQ
27/04	Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions	GL
14/04	Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel	GL
16/03	Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron	GL
26/02	Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights	GL
12/01	Structure Therapeutics : Corporate Presentation (d908c8)	PU
17/12	Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity	GL
11/12	Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs	GL
10/12	Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants	GL
08/12	Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants	GL
08/12	Structure Therapeutics : Aleniglipron Topline ACCESS Phase 2b Results	PU
08/12	Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron	GL
08/12	Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron	AQ
08/12	Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025	GL
07/11	Structure Therapeutics : Corporate Presentation (November 2025)	PU
06/11	Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights	GL
06/11	Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights	AQ
02/09/25	Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences	GL
02/09/25	Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences	AQ